Drug intelligence / Profile preview

OMTX005

Development stage: Unknown
Lead developer: Oncomatryx
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

OMTX005 is a humanized IgG1 monoclonal antibody targeting fibroblast activation protein alpha (FAPα), which is overexpressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of various solid tumors. It serves as the antibody backbone for the antibody-drug conjugate OMTX705, where it is conjugated to a cytolysin payload. OMTX005 itself has been explored as an unconjugated monoclonal antibody and as part of antibody-drug conjugate development for antineoplastic applications, specifically in neoplasms and solid tumors. The main developer is Oncomatryx Biopharma SL[1][3].

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on OMTX005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMTX005.

Explore the full profile